What are common alternatives to Amondys 45 (casimersen)?
Amondys 45 is a dystrophin-targeting therapy for Duchenne muscular dystrophy (DMD) that carries a mutation amenable to exon 45 skipping. Alternatives are usually other DMD treatments for different mutation “skipping” targets, or supportive standards of care.
Because “Amondys 45 alternative” often depends on the patient’s specific mutation, the closest options are other exon-skipping drugs matched to the exon involved.
Which exon-skipping drugs are used instead of Amondys 45?
For DMD exon skipping, patients and clinicians typically look for therapies matched to the exon that needs skipping. The relevant alternatives depend on the exon confirmed on genetic testing (for example, exon 51, exon 53, or exon 44).
How do you choose the right alternative—what matters most?
The main driver is whether the patient’s DMD mutation is amenable to a different exon-skipping approach than exon 45. Selection also depends on:
- The exact mutation confirmed by genetic testing (which exon is targeted)
- Prior treatments (if any) and how the patient tolerates them
- Dosing schedule and route expectations (these vary by product)
- Access and prescribing criteria in the patient’s country
Are there non-exon-skipping alternatives for Duchenne?
Yes. Some DMD care pathways include disease-modifying options that are not the same as exon skipping, plus supportive therapies (for example, corticosteroids and respiratory/cardiac management). Whether these are “alternatives” in the strict sense depends on whether the goal is mutation-specific dystrophin restoration versus broader disease management.
Are there alternatives if exon 45 skipping doesn’t fit?
If the patient’s mutation is not amenable to exon 45 skipping, clinicians generally pivot to:
- The exon-skipping therapy that matches the patient’s mutation (if available), or
- Non-exon-skipping disease management options
- Referral to a neuromuscular specialist to confirm eligibility and review clinical trials
What should you ask your neurologist to find the best Amondys 45 alternative?
Bring the genetic report and ask:
- Which exon skipping (if any) is appropriate for this exact mutation?
- Is the patient eligible for any other mutation-targeted DMD therapy?
- What outcomes should be expected (and how are they measured)?
- What is the monitoring plan (for example, lab tests and functional tracking) on the alternative?
Quick clarification to narrow recommendations
Which DMD mutation/exon is on the genetic test report (e.g., “skipping exon 45” confirmed, or a different exon like 51/53)? Also, which country are you in? The best alternative depends heavily on both.